

CURRICULUM VITAE

1. General information

NAME : **Vergison**

First NAME : **Anne, Madeleine**

Direction de la santé, Division de l'Inspection
Sanitaire

Languages: French (mother language), English (fluent, spoken & written), Portuguese (fluently spoken), Lëtzebuergesch (B1), Dutch (passive oral and written), Spanish (passive)

2. Professional experiences

- Head of division of de l'Inspection Sanitaire, Direction de la santé, since 01/10/2020
- Head of division of Médecine curative et de la qualité en santé, Direction de la santé, 01/04/2019 -30/09/2020
- Doctor at Division de la Médecine curative et de la qualité en santé, Direction de la santé, 01/09/2018 -01/04/2019
- Associate Medical director at medical direction, Union des Mutualités Socialistes, Brussels, March 2017-August 2018
- Medical advisor at medical direction, Union des Mutualités Socialistes, Brussels, May 2013-March 2017
- Consultant (“Résidente”) and then Associate director of the Paediatric Infectious Diseases Unit and Coordinator of the hospital epidemiology and infection control team in the ‘Hôpital Universitaire des Enfants Reine Fabiola’ (Brussels children’s university hospital), March 2002 - December 2012
- Consultant epidemiologist at the Clinique et Maternité Ste Elisabeth, Namur, for the management of a neonatal *Citrobacter koseri* outbreak (temporary contract) October 2011-June 2012
- Two one-year research grants from Erasme Foundation, ULB (Brussels Free University) October 1999-February 2002

- October 1995-September 1999: Fellowship in paediatrics, Hôpital Universitaire des Enfants Reine Fabiola (Brussels children's university hospital) and ULB Erasme (Brussels Free University Hospital)

3. Education

- June 1988: **Cambridge English proficiency**, Oxford College of Further Education, Oxford, UK
- June 1995: **Doctor in Medicine**
Free University of Brussels (Université Libre de Bruxelles (ULB))
- 1995 - 2001: **Post-graduate in Paediatrics** at the ULB
- 2004 – 2006: **Master in Public Health** (subspecialty Infection Control and hospital epidemiology) at the Catholic University of Leuven (Université Catholique de Louvain, (UCL))
- 2008 : Diplôme d'étude approfondies ; **PhD school**, ULB
- 16/02/2011 **PhD** in Medical Science entitled “Contribution à l'épidémiologie des infections à bactéries pyogènes à Gram positif chez l'enfant” (Contribution to the epidemiology of Gram positive pyogenic bacteria in children), ULB

4. Additional training

- Paediatric training in Lwiro (Kivu, Congo) November 1993-January 1994, a primary care paediatric centre within a program of malnutrition control of the CEMUBAC (Cooperation program of the Free University of Brussels)
- Complementary certificate in developing countries medicine 1994-1995: Université Libre de Bruxelles, ULB, Brussels, Belgium
- 1998: March to November: Paediatric Infectious Diseases, University of Brasilia, Brasil. Experience in HIV, congenital toxoplasmosis, tropical medicine, general paediatric infectious diseases
- Tropical medicine training course : 2 months 1998: Institute of Tropical Medicine, University of Brasilia, Brasil; *360 hours of theoretical and practical teaching in various aspects of tropical medicine, including epidemiology, diagnostic methods and therapeutic management of tropical diseases.*
- Special training in infectious diseases and clinical microbiology 4th edition One year 1999-2000 : Université Libre de Bruxelles, ULB, Brussels, Belgium

Microbiology, Hospital acquired infections, HIV infections, virology, paediatric infections, Mycobacteria, antibiotic use and control, monitoring of nosocomial infections, infectious disease immunology, prion disease, tropical pathology.

- October 1999 to December 2001: Microbiology Laboratory, National Reference Centre for Staphylococci, ULB-Erasme (Professor Marc Struelens), including stays in the microbiology laboratories of Prof. A. Andremont, Paris, France and Prof. G. Peters, Munster, Germany
- A comprehensive Review and Update of Pediatric Infectious Disease 10 - 15 July 2001: American Academy of Pediatrics, Chicago, USA
- Inter university training in antimicrobial therapy management 1st edition 3 months 2003 : Université Libre de Bruxelles, ULB, Brussels-Université de Liège, ULG, Liège-Université Catholique de Louvain, UCL, Brussels, Belgium
Regulatory framework for the marketing and dispensing of medicines, antibiotic policy coordination committee, standards, organisation and financing of hospitals; pharmaco-epidemiology of antibiotics; anti-infectives agents resistance problems; evidence based medicine and good clinical practice recommendations; quality of care and containment of antimicrobial resistance in hospitals.
- Training Course in Hospital Epidemiology ESCMID/SHEA 6-9 November 2005: ESCMID/SHEA and Société Française d'Hygiène Hospitalière, Beaune, France
Outbreak investigation and designing of an appropriate case control study.

5. Teaching experience

- 2009-2013: Assistant professor in Paediatrics, Université Libre de Bruxelles (ULB, Free University of Brussels)
- 2003-2012: Clinical supervision of paediatric fellows, post graduate paediatric fellowship and medicine graduation thesis supervisor, PhD supervisor
- Since 2002: Continuous medical education of medical doctors, students and nurses in paediatric infectious diseases and infection control.

6. Scientific and community activities

- 2005-2012 expert in the Pneumococcal Invasive Diseases Surveillance steering committee from the Belgian Institute of Public Health.
- Expert in the prevention of meningococcal disease and revision of infection control in school settings working group for the Belgian French speaking community.
- Expert in the Belgian working group for the Influenza immunisation of the health care workers, since 2006.

- Member of the Vaccine group of the National Superior Health Council since December 2007.
- Member of the Pedisurv (paediatric vaccine preventable disease surveillance) committee from the Belgian Institute of Public Health 2008-2012
- Chair of the scientific committee and co-chair of the organizing committee of 27th ESPID 2009 congress, Brussels, Belgium.
- Member of the National Influenza Scientific Committee for the H1N1 crisis in 2009
- European Society for Paediatric Infectious Diseases (ESPID) Board Member (2009-2012)
- Expert for European and Belgian Medical agency (Men B vaccine, pneumococcal serotypes replacement, harmonisation of Priorix SPC)
- Expert for the National Centre of Knowledge expertise (KCE): pneumococcal vaccines
- Member of the scientific committee of 29th ESPID 2011 congress, Den Haag, The Netherlands.
- European Society for Paediatric Infectious Diseases (ESPID) Research Committee Member (2010-2013)
- World Society for Pediatric Infectious Diseases (WSPID): Board member and general secretary since 2012-2014
- Member of the Belgian Insurance Scientific Association (ASMA) 2013-2018 and member of the administration board 2015-2018
- Member of the Belgian Drug reimbursement committee (Commission de remboursement des médicaments - Commissie voor terugbetaling van geneesmiddelen) (INAMI-RIZIV) 2014-2018
- Member of the Superior Medical Committee for Invalidity (INAMI-RIZIV) 2014-2018
- Member of the Accreditation direction group (INAMI-RIZIV) 2014-2018
- Member of the National Committee for Quality Promotion (CNPQ) (INAMI-RIZIV) since 2015-2018
- Member of the planning committee (SPF Public Health) 2015-2018
- Member of the Administration board of FARMAKA 2015-2018
- Member of the National College on Work incapacity 2016-2018
- Participations to jury member of Consensus INAMI-RIZIV on rational use of hypolipemiant drugs (2014), rational use of GLP-1 agonists in type 2 diabetes patients (2016) and on rational antibiotic use in children in ambulatory settings (2016).
- Member of the Conseil Scientifique des Maladies Infectieuses of Luxembourg since November 2020

7. Grants and awards

Erasme Foundation 2 one-year salary grants from 1999 until 2002

Belgian Kids Fund 9 Grants for salaries for several projects from 2003 until 2009

ASBL Iris Recherche

- Grant in 2007 for a project entitled : Epidemiology and dynamics of nasopharyngeal flora in kindergarten aged children: 50,000€
- Grant in 2009 for a project entitled: management of group A *Streptococcus* pharyngitis in children, an equivalence study, multicentre randomised control trial: 30,000€

Fond National pour la Recherche Scientifique

- Grant in 2007: Epidemiology and dynamics of nasopharyngeal flora in kindergarten aged children: 10,000€

ESCMID Research grant

- Grant in 2008: Evolution of *Streptococcus pneumoniae* epidemiology in Belgian children: 20,000€

Research grant from MSD

- Grant in 2012: Fungal biomarkers in paediatric patients with haematological malignancies: 30,000€

Awards

Prix Victor Conard awarding the medical graduating student who particularly distinguished him/herself towards classmates and university community, June 1995, Medical association of former Free University of Brussels students.

8. International scientific publications (peer reviewed journals)

1. Severe disease due to group A streptococcus in Belgium. G. Hanquet, H. Goossens, G. Top, et al. Eurosurveillance Weekly June 2004
2. Polyclonal emergence and importation of community-acquired methicillin resistant *Staphylococcus aureus* strains harboring Panton-Valentine leukocidin genes in Belgium. O. Denis, A. Deplano, H De Beenhouwer, et al. Antimicrob Chemother. 2005 Dec;56(6):1103-6
3. Antimicrobial therapy for intra-abdominal infections: guidelines from the Infectious Disease Advisory Board (IDAB) Laterre PF, Colardyn F, Delmee M, et al. IDAB. Acta Chir Belg. 2006 Jan-Feb;106(1):2-21.
4. Epidemiologic Features of Invasive Pneumococcal Disease in Belgian Children: Passive Surveillance Is Not Enough. Anne Vergison, David Tuerlinckx, Jan Verhaegen, Anne Malfroot for the Belgian Invasive Pneumococcal Disease Study Group. Pediatrics 2006;118 e801-e809
5. A pragmatic clinical score to reduce unnecessary antibiotic use in children with pharyngitis in developing countries. Smeesters P.R., Campos Junior D., Van Melderden L, de Aguiar E., Vanderpas J., Vergison A. Pediatrics. 2006. Dec;118(6):e1607-11

6. Differences between Belgian and Brazilian Group A *Streptococcus* Epidemiologic Landscape. Smeesters P.R., Vergison A., Campos Junior D., et al. PLoS One. 2006. Dec 20;1:e10.
7. National survey of molecular epidemiology of *Staphylococcus aureus* colonization in Belgian Cystic Fibrosis patients. A. Vergison, O. Denis, A. Deplano, et al. Journal of Antimicrobial chemotherapy 2007 May;59(5):893-9.
8. *Streptococcus pneumoniae* incidence in western Europe. Anne Vergison and Ralf R. Reinert, Lancet Infectious Diseases 2007 Apr;7(4):240-2.
9. Prevention of childhood rotavirus disease through the use of ROTARIX™ and ROTATEQ™ vaccines. Philippe Lepage and Anne Vergison. Expert Opin Biol Ther. 2007 Dec;7(12):1881-92.
10. Microbiology of otitis media: a moving target? Anne Vergison. Vaccine 2008 26S7: G5-G10
11. Genetic diversity of Group A *Streptococcus* M protein: implications for typing and vaccine development. Smeesters PR, Mardulyn P, Vergison A, et al. Vaccine. 2008; 26(46):5835-42.
12. Emerging fluoroquinolone-non-susceptible group A streptococci in two different paediatric populations. Smeesters PR, Vergison A, Junior DC, Van Melderren L Int J Antimicrob Agents. 2009; 34(1):44-9.
13. Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a *Staphylococcus aureus* small-colony variant strain isolated from a cystic fibrosis patient: study of antibiotic combinations. Nguyen HA, Denis O, Vergison A, et al. Antimicrob Agents Chemother. 2009; 53(4):1443-9.
14. Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a *Staphylococcus aureus* small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. Nguyen HA, Denis O, Vergison A, et al. Antimicrob Agents Chemother. 2009; 53(4):1434-42.
15. *Kytococcus schroeteri* infection of a ventriculoperitoneal shunt in a child. Jourdain S, Miendje Deyi VY, Musampa K, Wauters G, Denis O, Lepage P, Vergison A. Int J Infect Dis. 2009 Jul;13(4):e153-5.
16. Group A *Streptococcus* virulence and host factors in two toddlers with rheumatic fever following toxic shock syndrome Pierre Robert Smeesters, Pierre-Alexandre Dreze, Dominique Biarent, Laurence Van Melderren, Anne Vergison. Int J Infect Dis. 2010 May;14(5):e403-9
17. Otitis Media and Its Consequences: Beyond the Earache. Anne Vergison, Ron Dagan, Adriano Arguedas, Jan Bonhoeffer, Robert Cohen, Ingerborg Dhooze, Alejandro Hoberman, Johannes Liese, MD, Paola Marchisio, Arto A Palmu, G. Thomas Ray, MBA, Elizabeth A Sanders, Eric A Simões, Matti Uhari, Johan Van Eldere, Stephen I Pelton. Lancet Infect Dis. 2010 Mar;10(3):195-203.
18. Surveillance of invasive pneumococcal disease in 30 EU countries: Towards a European system? Hanquet G, Perrocheau A, Kissling E, et al.; the ECDC country experts for pneumococcal disease. Vaccine. 2010
19. Differences in nasopharyngeal bacterial carriage in preschool children from different socio-economic origins. Jourdain S, Smeesters PR, Denis O, Dramaix M, Sputael V, Malaviolle X, Van Melderren L, Vergison A. Clin Microbiol Infect. 2010 Oct 26.

20. Rotavirus vaccines in Belgium: policy and impact. Braeckman T, Van Herck K, Raes M, et al. *Pediatr Infect Dis J*. 2011 Suppl: S21-4.
21. Impact of conjugate 7-valent vaccination in Belgium: Addressing methodological challenges. Hanquet G, Lernout T, Vergison A, et al.; for the Belgian IPD Scientific Committee. *Vaccine*. 2011 Apr 5;29(16):2856-64.
22. Enteroviral Infection of a Child with a Cardiac Prosthetic Device S. Blumental, M. Reynders, A. Willems, D Biarent, R. Duttman, P. Lepage, and A. Vergison. *Clin Infect Dis*, 2011 Mar;52(6):710-6.
23. Reduction in Pediatric Rotavirus-related Hospitalizations After Universal Rotavirus Vaccination in Belgium. Raes M, Strens D, Vergison A, et al. *Pediatr Infect Dis J*. 2011 Jul;30(7):e120-5
24. Impact of rotavirus vaccination on laboratory confirmed cases in Belgium. G. Hanquet, G. Ducoffre G, A. Vergison, et al. *Vaccine* 2011 Jun 24;29(29-30):4698-703
25. Pandemic A/H1N1v influenza 2009 in hospitalized children: a multicenter Belgian survey. Blumental S, Huisman E, Cornet MC, et al. *BMC Infect Dis*. 2011 Nov 7;11:313.
26. Heterogeneity of disease and clones of community onset methicillin resistant *Staphylococcus aureus* in children attending a paediatric hospital in Belgium. Vergison A, Nobre Machado A, Deplano A, et al. *Clin Microbiol Infect Clin Microbiol Infect*. 2012 Aug;18(8):769-77.
27. Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. Taylor S, Marchisio P, Vergison A, et al. *Clin Infect Dis*. 2012 Mar 15.
28. Antibiotic Therapy for Pediatric Community-Acquired Pneumonia: Do We Know When, What and For How Long to Treat? Esposito S, Cohen R, Domingo JD, et al. *Pediatr Infect Dis J*. 2012 Mar 29.
29. Challenges in estimating the impact of pneumococcal conjugate vaccines through surveillance. Vergison A, Hanquet G. *Pediatr Infect Dis J*. 201 Apr;31(4):400-3.
30. Pneumococcal conjugate vaccines and otitis media. Taylor S, Marchisio P, Vergison A, et al. *Int J Otolaryngol*. 2012;2012:
31. The Burden of Childhood Pneumonia in the Developed World: A Review of the Literature. Madhi SA, De Wals P, Grijalva CG, et al. *Pediatr Infect Dis J*. 2012 Oct 24.
32. RotaBel Study Group. Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study. Braeckman T, Van Herck K, Meyer N, et al.; *BMJ*. 2012 Aug 8;345:e4752.
33. Impact of rotavirus vaccines on rotavirus disease. Lepage P, Vergison A. *Expert Rev Anti Infect Ther*. 2012 May;10(5):547-61.
34. Prospective evaluation of Coris Influa-A&B Respi-Strip and of BinaxNOW Influenza A&B assay against viral culture and real-time PCR assay for detection of 2009 pandemic influenza A/H1N1v in Belgian patients. Reynders M, De Foor M, Maaroufi Y, et al. *Acta Clin Belg*. 2012 Mar-Apr;67(2):94-8.
35. Evaluation of a WHO-validated serotype-specific serological assay for the diagnosis of pneumococcal etiology in children with community-acquired pneumonia. Tuerlinckx D, Smet J, De Schutter I, et al. *Pediatr Infect Dis J*. 2013 Jul;32(7):e277-84.

36. Dynamic pattern and genotypic diversity of *Staphylococcus aureus* nasopharyngeal carriage in healthy pre-school children. Blumental S, Deplano A, Jourdain S, De Mendonça R, Hallin M, Nonhoff C, Rottiers S, Denis O, Vergison A. *J Antimicrob Chemother.* 2013 Jul;68(7):1517-23
37. ARPEC Project Group Members. The antibiotic resistance and prescribing in European Children project: a neonatal and pediatric antimicrobial web-based point prevalence survey in 73 hospitals worldwide. Versporten A, Sharland M, Bielicki J, et al. *Pediatr Infect Dis J.* 2013 Jun;32(6):e242-53
38. Acute otitis media in young children -what do parents say? Barber C, Ille S, Vergison A, Coates H. *Int J Pediatr Otorhinolaryngol.* 2014 Feb;78(2):300-6
39. Pneumococcal aetiology and serotype distribution in paediatric community-acquired pneumonia. De Schutter I, Vergison A, Tuerlinckx D, et al. *PLoS One.* 2014 Feb 18;9(2):e89013
40. ; RotaBel study group. Higher proportion of G2P[4] rotaviruses in vaccinated hospitalized cases compared with unvaccinated hospitalized cases, despite high vaccine effectiveness against heterotypic G2P[4] rotaviruses. Matthijssens J, Zeller M, Heylen E, et al *Clin Microbiol Infect.* 2014 Oct;20(10):O702-10
41. Zhang SY. TLR3 deficiency in herpes simplex encephalitis: high allelic heterogeneity and recurrence risk. Lim HK, Seppänen M, Hautala T, et al., *Neurology.* 2014 Nov 18;83(21):1888-97
42. Avibactam confers susceptibility to a large proportion of ceftazidime-resistant *Pseudomonas aeruginosa* isolates recovered from cystic fibrosis patients. Chalhoub H, Tunney M, Elborn JS, et al. *J Antimicrob Chemother.* 2015 May;70(5):1596-8
43. ; ARPEC Project Group Members. Variation in paediatric hospital antibiotic guidelines in Europe. Spyridis N, Syridou G, Goossens H, et al. *Arch Dis Child.* 2016 Jan;101(1):72-6
44. Antimicrobial Susceptibility of *Pseudomonas aeruginosa* Isolated from Cystic Fibrosis Patients in Northern Europe. Mustafa MH, Chalhoub H, Denis O, et al. *Antimicrob Agents Chemother.* 2016 Oct 21;60(11):6735-6741.
45. COVID-19 trends and severity among symptomatic children aged 0-17 years in 10 European Union countries, 3 August 2020 to 3 October 2021. Bundle N, Dave N, Pharris A, et al. *Euro Surveill.* 2021 Dec;26(50)
46. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Funk T, Pharris A, Spiteri G, et al. COVID study groups. *Euro Surveill.* 2021 Apr;26(16)
47. Age-specific associations between underlying health conditions and hospitalisation, death and in-hospital death among confirmed COVID-19 cases: a multi-country study based on surveillance data, June to December 2020. Funk T, Innocenti F, Gomes Dias J et al. *Euro Surveill.* 2022 Sep;27(35)
48. Surveillance of Indoor Air Concentration of Volatile Organic Compounds in Luxembourgish Households. Alvarez-Vaca D, Duca RC, Borrás-Santos A et al. *Int J Environ Res Public Health.* 2022 Apr 30;19(9):5467.
49. Vaughan AM, Cenciarelli O, Colombe S, A large multi-country outbreak of monkeypox across 41 countries in the WHO European Region, 7 March to 23 August 2022. *Euro Surveill.* 2022 Sep;27(36)
50. Investigation of an international outbreak of multidrug-resistant monophasic *Salmonella* Typhimurium associated with chocolate products, EU/EEA

- and United Kingdom, February to April 2022. Larkin L, Pardos de la Gandara M, Hoban A, et al. *Euro Surveill.* 2022 Apr;27(15):
51. Risk reduction of severe outcomes in vaccinated COVID-19 cases: an analysis of surveillance data from Estonia, Ireland, Luxembourg and Slovakia, January to November 2021. Marrone G, Nicolay N, Bundle N, et al. *Euro Surveill.* 2022 Feb;27(7)
 52. Risk of hospitalization and death for healthcare workers with COVID-19 in nine European countries, January 2020-January 2021. Ferland L, Carvalho C, Gomes Dias J, et al. *J Hosp Infect.* 2022 Jan;119:170-174.
 53. A Molecular and Epidemiological Investigation of a Large SARS-CoV-2 Outbreak in a Long-Term Care Facility in Luxembourg, 2021. Ernst C, Pires-Afonso Y, Bejko D, et al. *Geriatrics (Basel).* 2023 Jan 26;8(1):19
 54. Multisystem inflammatory syndrome in children during the first two years of the COVID-19 pandemic in Luxembourg. Ooms C, Mossong J, Vergison A, et al. *Front Pediatr.* 2023 Apr 5;11:1141074.
 55. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg. Ernst C, Bejko D, Gaasch L, et al. *J.Euro Surveill.* 2024 Jan;29(4).
 56. Epidemiology of reported cases of leptospirosis in the EU/EEA, 2010 to 2021. Beauté J, Innocenti F, Aristodimou A, et al. *Euro Surveill.* 2024 Feb;29(7).